COMP <GO>
AQST vs EOLS // GROSS PROFIT MARGIN
Aquestive Therapeutics Inc. (NASDAQ) VS. Evolus Inc. (NASDAQ) • 15-METRIC TALLY: AQST 1
— EOLS 7
▲ GROSS PROFIT MARGIN LEADER: EOLS
LAST: $3.77 (-3.08%) • MKT CAP: $488.2M
gross-margins
58.30%
LAST: $7.16 (-2.58%) • MKT CAP: $485.5M
gross-margins
66.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AQST VS. EOLS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AQST | EOLS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 58.30% | 66.30% | -8.00 | EOLS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -10.45% | -9.20% | -1.25 | EOLS | /fcf-yield <GO> |
| Operating Margin | -60.00% | -11.00% | -49.00 | EOLS | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -17.40% | -42.60 | EOLS | /net-margins <GO> |
| Revenue Growth (YoY) | -22.60% | 11.60% | -34.20 | EOLS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 0.20 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 4/9 | -1.00 | EOLS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 39.2 | 46.4 | -7.20 | EOLS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $488.2M | $485.5M | $2.8M | AQST | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AQST REV | EOLS REV | AQST GROSS % | EOLS GROSS % | AQST FCF | EOLS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $44.5M | $297.2M | 58.3% | 66.3% | -$53.0M | -$45.7M |
| FY 2024 | $57.6M | $266.3M | 69.0% | 68.5% | -$35.9M | -$19.5M |
| FY 2023 | $50.6M | $202.1M | — | — | -$6.4M | -$34.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AQST // BETA —
EOLS // BETA —